Specific and non-specific binding of a tracer for the translocator-specific protein in schizophrenia: an [11C]-PBR28

Tiago Reis Marques1,2,3, Mattia Veronese4, David R Owen5

  • 1Psychiatric Imaging Group, MRC London Institute of Medical Sciences (LMS), Hammersmith Hospital, Imperial College London, London, UK. t.dos-reis-marques@lms.mrc.ac.uk.

Abstract

Insights

Positron emission tomography (PET) studies in schizophrenia show variable results due to non-displaceable binding (VND). This study quantified VND in schizophrenia patients using a TSPO ligand, finding it similar to healthy controls, suggesting non-specific binding does not explain PET discrepancies.

Area of Science:

  • Neuroimaging
  • Neuroinflammation
  • Psychiatric Disorders

Background:

  • Mitochondrial 18-kDa translocator protein (TSPO) is a marker of activated microglia, measurable via positron emission tomography (PET).
  • Previous TSPO PET findings in schizophrenia have been inconsistent, potentially due to variations in non-displaceable binding (VND).

Purpose of the Study:

  • To quantify VND in schizophrenia patients using the TSPO ligand XBD173 to block the radioligand [11C]-PBR28.
  • To determine if differences in VND account for discrepant TSPO PET findings in schizophrenia.

Main Methods:

  • Seven high-affinity binder (HAB) schizophrenia patients underwent two [11C]PBR28 PET scans: baseline and post-XBD173 administration.
  • VND was quantified using an occupancy plot with 2-tissue compartment model (2TCM) kinetic estimates, with and without vascular correction, and the SIME method.

Main Results:

  • A global reduction in [11C]PBR28 uptake was observed after XBD173 administration in all patients.
  • The population VND was estimated at 1.99 mL/cm3 (95% CI 1.90–2.08), with similar fractional TSPO occupancy when vascular correction was applied.
  • A substantial component of the [11C]PBR28 signal in schizophrenia patients represents specific binding to TSPO.

Conclusions:

  • The non-displaceable binding (VND) in schizophrenia patients is similar to that reported in healthy controls.
  • Discrepant TSPO PET findings in schizophrenia are not attributable to differences in non-specific binding between patient and control groups.
  • These findings clarify the interpretation of TSPO PET imaging in schizophrenia research.